Anthera Pharma (ANTH) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results
August 9, 2016 8:35 AM EDTMet enrollment target in SOLUTION study and enrolled first patient in SIMPLICITY study of SollpuraSuccessful sachet manufacturing to support SIMPLICITY study and commercial-scale lipase demonstration batchFirst patient enrolled in pivotal CHABLIS 7.5 clinical study of blisibimodPositive trends from analysis of BRIGHT-SC Phase 2 clinical study
HAYWARD, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today provided a business update and reported financial results for the second quarter ended June 30, 2016.
Recent Developments and Business Highlights:
Sollpura (liprotamase) Exocrine Pancreatic Insufficiency... More
